Immuno Cure’s Anti-Δ42PD1 Antibody Project Awarded HKSAR Government’s RAISe+ Scheme Funding
- Written by Immuno Cure (醫克生物)
HONG KONG SAR - Media OutReach Newswire - 3 June 2024 - Immuno Cure BioTech ("Immuno Cure") is delighted to announce that our pipeline product "Anti-Δ42PD1 Antibody against hepatocellular carcinoma (HCC)", sublicensed to Orimmune BioTech Limited ("Orimmune"), which has recently been awarded significant funding from the HKSAR Government's...





